Synlogic   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2014)

Organization Overview

First Clinical Trial
2017
NCT03179878
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Synlogic

Active Ingredients

Drugs in Phase 2 Trials (4)

Key: Synlogic (2) Acquired (2)

mrx34 (2 trials)

synb1020 (2 trials)

synb1618 (3 trials)

urea (1 trial)

Drugs in Phase 1 Trials (5)

atezolizumab (tecentriq) (1 trial)

synb1353 (1 trial)

synb1891 (1 trial)

synb1934 (1 trial)

synb8802 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Liver Cirrhosis (Phase 2)

Lymphoma (Phase 1)

Phenylketonurias (Phase 2)

Urea Cycle Disorders, Inborn (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 9